MRC1 and neoplasm: Particularly, TP‐16 treatment switched the polarization of macrophages from the CD45+CD11b+F4/80+CD206+ immunosuppressive M2 phenotype (pro‐tumor) to the CD45+CD11b+F4/80+MHC‐II+ proinflammatory M1 phenotype (anti‐tumor) (Fig 4A and B).